newsfilter
← Latest News
GlobeNewswire·

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ